GlassScriptPhysician profile
Marcos M Chertman
NPI 1003865262
$4,044.68
in general payments reported to CMS, 2019-2025
30 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $17.67 · 2021: $49.19 · 2022: $684 · 2023: $841 · 2024: $912 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $676.01 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $553.42 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Mannkind Corporation | $351.37 | 2019-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $332.98 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $317.36 | 2024-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $273.22 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $206.76 | 2022-2025 | |
| Corcept Therapeutics | $185.71 | 2019-2025 | Korlym |
| Insulet Corporation | $160.78 | 2023-2025 | Omnipod |
| Abbott Laboratories | $144.63 | 2022-2023 | Epic |
| Recordati_rare_diseases_inc. | $127.47 | 2025 | Isturisa |
| Shire North American Group INC | $119.37 | 2019 | |
| Radius Health, INC. | $106.87 | 2024-2025 | |
| Abbvie INC. | $55.05 | 2019-2025 | |
| Ibsa Pharma INC. | $49.73 | 2022-2025 | Tirosint, Licart, Flector |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $46.10 | 2025 | Twiist |
| Dexcom, INC. | $39.36 | 2023-2025 | Dexcom G6 Transmitter |
| Ascend Therapeutics US, LLC | $36.00 | 2021 | |
| Madrigal Pharmaceuticals | $28.57 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $28.57 | 2025 | Imcivree |
| Kyowa Kirin, INC. | $26.68 | 2024 | Crysvita |
| Amarin Pharma, INC. | $24.18 | 2022 | |
| Neurocrine Biosciences, INC. | $23.85 | 2025 | |
| Ascendis Pharma Endocrinology INC | $22.01 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $21.43 | 2025 | Strensiq |
| Halozyme INC | $20.98 | 2023 | |
| Horizon Therapeutics Plc | $19.04 | 2023 | Tepezza |
| Cequr Corporation | $16.90 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $15.24 | 2019 | |
| Alvogen INC | $15.04 | 2023 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Chertman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.